Phase 1b/II study of cancer sternness inhibitor napabucasin (BBI-608) in combination with FOLFIRI plus /- bevacizumab (bev) in metastatic colorectal cancer (mCRC) patients (pts).

被引：28
|
作者：
Bendel, Johanna C.
Hubbard, Joleen Marie
O'Neil, Bert H.
Jonker, Derek J.
Starodub, Alexander
Peyton, James D.
Pitot, Henry C.
Halfdanarson, Thorvardur Ragnar
Nadeau, Benjamin Rolland
Zubkus, John D.
Adesunloye, Bamidele
Edenfield, William Jeffery
Li, Youzhi
Li, Wei
Grothey, Axel
Borodyansky, Laura
Li, Chiang
机构：
来源：
JOURNAL OF CLINICAL ONCOLOGY | 2017年 / 35卷
关键词：
D O I：
10.1200/JCO.2017.35.15_suppl.3529
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
3529
引用
收藏
页数：5
相关论文
共 50 条
  • [41] Retrospective review of FOLFIRI with or without bevacizumab (bev) for patients (pts) with metastatic colorectal cancer (mCRC): Reviewing a single-center standard clinical practice
    Maroun, Jean Alfred
    Marginean, Horia
    JOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (03)
  • [42] OXALIPLATIN AND CAPECITABINE (XELOX) PLUS BEVACIZUMAB (BEVA) FOR ELDERLY PATIENTS (PTS) WITH METASTATIC COLORECTAL CANCER (mCRC): BOXE, A PHASE II TRIAL
    Rosati, Gerardo
    Cordio, Stefano
    Leo, Silvana
    Daniele, Bruno
    Butera, Alfredo
    ANNALS OF ONCOLOGY, 2011, 22 : v104 - v104
  • [43] 5-FLUOROURACIL, LEUCOVORIN AND IRINOTECAN (FOLFIRI) PLUS BEVACIZUMAB (BV) IN PATIENTS WITH METASTATIC COLORECTAL CANCER (MCRC): A MULTICENTER PHASE II TRIAL
    Cordio, S.
    Parra, Soto H. J.
    Pumo, V
    Condorelli, S.
    Latteri, F.
    Sambataro, D.
    Rosati, G.
    Aprile, G.
    Fassari, G.
    De Pauli, F.
    Rimassa, L.
    Bordonaro, R.
    ANNALS OF ONCOLOGY, 2009, 20
  • [44] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Gorbunova, Vera
    Beck, J. Thaddeus
    Hofheinz, Ralf-Dieter
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    Mangel, Laszlo
    Fernandez, Elena Elez
    Deming, Dustin A.
    Ramanathan, Ramesh K.
    Torres, Alison H.
    Sullivan, Danielle
    Luo, Yan
    Berlin, Jordan D.
    BRITISH JOURNAL OF CANCER, 2019, 120 (02) : 183 - 189
  • [45] A phase 2 randomised study of veliparib plus FOLFIRI±bevacizumab versus placebo plus FOLFIRI±bevacizumab in metastatic colorectal cancer
    Vera Gorbunova
    J. Thaddeus Beck
    Ralf-Dieter Hofheinz
    Pilar Garcia-Alfonso
    Marina Nechaeva
    Antonio Cubillo Gracian
    Laszlo Mangel
    Elena Elez Fernandez
    Dustin A. Deming
    Ramesh K. Ramanathan
    Alison H. Torres
    Danielle Sullivan
    Yan Luo
    Jordan D. Berlin
    British Journal of Cancer, 2019, 120 : 183 - 189
  • [46] Evaluation of panitumumab (pmab) plus fluorouracil, leucovorin, and irinotecan (FOLFIRI) after first-line bevacizumab (bev) in patients (pts) with metastatic colorectal cancer (mCRC): A subgroup analysis of study 181
    Peeters, M.
    Price, T. J.
    Strickland, A. H.
    Ciuleanu, T. E.
    Scheithauer, W.
    O'Reilly, S.
    Keane, M. M.
    Spigel, D. R.
    Tian, Y.
    Krishnan, K.
    JOURNAL OF CLINICAL ONCOLOGY, 2011, 29 (15)
  • [47] Phase 2 study of veliparib plus FOLFIRI ± bevacizumab versus placebo plus FOLFIRI ± bevacizumab in metastatic colorectal cancer.
    Gorbunova, Vera
    Beck, Thaddeus
    Hofheinz, Ralf
    Garcia-Alfonso, Pilar
    Nechaeva, Marina
    Gracian, Antonio Cubillo
    JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (15)
  • [48] FOLFOXIRI plus bevacizumab (bev) followed by maintenance with bev alone or bev plus metronomic chemotherapy (metroCT) in metastatic colorectal cancer (mCRC): The phase II randomized MOMA trial
    Falcone, A.
    Cremolini, C.
    Loupakis, F.
    Lonardi, S.
    Casagrande, M. E.
    Murgioni, S.
    Salvatore, L.
    Masi, G.
    Fanotto, V.
    Granetto, C.
    Marmorino, F.
    Ginocchi, L.
    Ziampiri, S.
    Grande, R.
    Tonini, G.
    Delfanti, S.
    Di Donato, S.
    Fontanini, G.
    Boni, L.
    Zagonel, V.
    ANNALS OF ONCOLOGY, 2016, 27
  • [49] Safety and efficacy of MPDL3280A (anti-PDL1) in combination with bevacizumab (bev) and/or FOLFOX in patients (pts) with metastatic colorectal cancer (mCRC).
    Bendell, Johanna C.
    Powderly, John D.
    Lieu, Christopher Hanyoung
    Eckhardt, S. Gail
    Hurwitz, Herbert
    Hochster, Howard S.
    Murphy, Janet E.
    Funke, Roel Peter
    Rossi, Cheryl
    Wallin, Jeffrey
    Waterkamp, Daniel
    Pishvaian, Michael J.
    JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (03)
  • [50] Impact of bevacizumab (bev) on overall survival (OS) in patients (pts) with metastatic colorectal cancer (MCRC): A population-based study
    Renouf, D. J.
    Lim, H. J.
    Speers, C.
    Villa, D.
    Gill, S.
    Blanke, C. D.
    O'Reilly, S. E.
    Kennecke, H.
    JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
12345